Genome-wide CRISPR-Cas9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma
Open Access
- 4 January 2025
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (4) , 916-931
Abstract
Background: Registered systemic treatment options for glioblastoma patients are limited. The phase II REGOMA trial suggested an improvement of median overall survival in progressive glioblastoma by the multi-tyrosine kinase inhibitor regorafenib. This has not been confirmed by GBM AGILE. So far, regorafenib has been administered as monotherapy or as an addition to standard of care in newly diagnosed glioblastoma. Rational combination therapies involving regorafenib might be a reasonable strategy. Here, we aimed at identifying functionally instructed combination therapies involving regorafenib. Methods: We applied a genome-wide CRISPR-Cas9-based functional genomics target discovery approach using activation and knockout screens followed by genetic, pharmacological, functional validations. Regorafenib-induced molecular alterations were assessed by RNA sequencing and DigiWest. We investigated selected functionally instructed combination therapies in three orthotopic glioma mouse models in vivo (syngeneic SMA560/VM/Dk model and two xenograft models) and performed immunohistochemistry of post-treatment brains. Results: We identified potential modifiers of regorafenib response, including BCL2, BCL2L1, ITGB3, FOXC1, SERAC1, ARAF, and PLCE1. The combination of regorafenib with Bcl-2/Bcl-xL inhibition was superior to both monotherapies alone in vitro, ex vivo, and in vivo. We identified regorafenib-induced regulations of the Bcl-2 downstream target chemokine receptor 1 (CCR1) as one potential underlying molecular mediator. Furthermore, regorafenib led to changes in the myeloid compartment of the glioma-associated microenvironment. Conclusions: This preclinical study uses a functional genomics-based target discovery approach with subsequent validations involving regorafenib. It serves as a biological rationale for clinical translation. Particularly, an investigation of the combination of regorafenib plus navitoclax within a clinical trial is warranted.Keywords
Funding Information
- Adolf Leuze Stiftung
- Medical Faculty Tübingen
- Else Kröner Forschungskolleg (2019_Kolleg_14)
- Deutsche Forschungsgemeinschaft
- Germany’s Excellence Strategy, Cluster of Excellence (EXC 2180, 390900677)
This publication has 66 references indexed in Scilit:
- Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?Journal of Neuro-Oncology, 2022
- Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomasJournal of Neuro-Oncology, 2022
- Argyrin F Treatment‐Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental GliomaAdvanced Therapeutics, 2021
- Methods for High-throughput Drug Combination Screening and Synergy Scoring2018
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With GlioblastomaJAMA, 2017
- RETRACTED: Involvement of Notch‐1 in Resistance to Regorafenib in Colon Cancer CellsJournal of Cellular Physiology, 2015
- Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancerInternational Journal of Cancer, 2013
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first‐line treatment of patients with glioblastoma multiformeCancer, 2010
- Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA)Acta Neuropathologica, 1980